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Background: The prevalence of drug-resistant bacteria has encouraged the search for novel antimicrobial
compounds. Food-associated microorganisms, as a source of new antibiotics, have recently received considerable
attention. The objective of this study was to find novel antimicrobial agents produced by food microorganisms.
Results: A bacterial strain B7, which has potent antimicrobial activity, was isolated from a sample of dairy waste.
This strain was identified as Paenibacillus ehimensis based on the 16S rRNA gene sequence analysis, physiological
and biochemical characterization. Two active compounds (PE1 and PE2) were obtained from P. ehimensis B7.
Mass spectrometry (MS) analysis showed that the molecular masses of PE1 and PE2 were 1,114 and 1,100 Da,
respectively. The tandem MS and amino acid analysis indicated that PE1 and PE2 were analogs of polypeptin,
and PE2 was characterized as a new member of this family. Both compounds were active against all tested
bacterial pathogens, including methicillin resistant Staphylococcus aureus, Escherichia coli, and pan-drug resistant
Pseudomonas aeruginosa clinical isolate. Time-kill assays demonstrated that at 4 × MIC (minimum inhibitory
concentration), PE1 and PE2 rapidly reduced the number of viable cells by at least 3-orders of magnitude,
indicating that they were bactericidal antibiotics.
Conclusions: In the present work, two cationic lipopeptide antibiotics (PE1 and PE2) were isolated from P.
ehimensis B7 and characterized. These two peptides showed broad antimicrobial activity against all tested human
pathogens and are worthy of further study.
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Clinical infection due to drug-resistant bacteria is a serious
challenge to patient safety [1,2]. In the United States,
methicillin-resistant Staphylococcus aureus (MRSA) is esti-
mated to cause ~19,000 deaths per year [3]. MRSA is also a
considerable threat in China, where the resistance ratio
among hospital-acquired infections reaches almost 90%
[4,5]. Apart from MRSA, several multidrug-resistant
(MDR) and pan-drug-resistant (PDR) Gram-negative bac-
teria, including Pseudomonas aeruginosa, Escherichia coli,
Acinetobacter baumannii, and Klebsiella pneumoniae, are* Correspondence: hzhwxsy@126.com
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reproduction in any medium, provided the oremerging as additional major threat to public health [6,7].
Unfortunately, few novel drugs have been developed specif-
ically for MDR/PDR Gram-negative bacteria in recent years
[8-10]. The development of new antimicrobial agents
cannot keep up with the evolution of bacterial resistance.
Thus, more efforts should be placed on discovering and
developing new antimicrobial agents.
As a source of new antibiotics, food-associated microor-
ganisms have recently received increased attention. The
well-known active compounds produced by these strains
are peptide antibiotics, such as lantibiotics and lipopeptides
[11-13]. Many of them are potentially useful in medical and
food applications due to their low intestinal toxicity. To
obtain antimicrobial agents that are novel safe and potent,
a lot of food bacteria were isolated and screened for their
antimicrobial activity. In this work, strain B7, a new bacter-
ial isolate from a sample of dairy waste, was found toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Gram-negative human pathogens. Based on the 16S
rRNA gene sequence analysis as well as physiological
and biochemical characterization, strain B7 was identified
as Paenibacillus ehimensis. After isolation and purification
of the fermentation products, the chemical structure and
biological characteristics of the active compounds produced
by P. ehimensis B7 were determined.
Methods
Strains and culture conditions
Samples of dairy waste were collected from a local dairy
industry in Wuxi. The dairy waste samples were suspended
in 0.1% sterile peptone water and antibiotic producing
strains were isolated using a competitive inhibition method
as previously described [14]. Nutrition broth was used
for routine culture. The active compounds were produced
in synthetic Katznelson and Lochhead (KL) medium,
which had the following composition (in g/L): glucose, 5;
(NH4)2SO4, 1.5; MgSO4
. 7H2O, 0.2; NaCl, 0.1; CaC12, 0.1;
FeSO4
. 7H2O, 0.01; ZnSO4, 0.01; MnSO4
. H2O, 0.0075; and
KH2PO4 2.7. The medium was autoclaved and brought to
a pH of 7.2. Staphylococcus epidermis CMCC 26069 was
purchased from the National Center for Medical Culture
Collections. S. aureus ATCC 43300, S. aureus ATCC
25923, E. coli ATCC 35218, and P. aeruginosa ATCC
27853 were purchased from the American Type Culture
Collection (ATCC). Clinical isolates (P. aeruginosa 5215
and E. coli 5539) were isolated from patients at the Fourth
People’s Hospital of Wuxi, Wuxi, China. The tested strains
that were used to determine the sensitivity to the active
compounds were routinely grown at 37°C on a nutrient
agar or in a nutrient broth. For long-term storage, all of
the strains were stored in 20% (v/v) glycerol at −80°C. This
study was approved by the Ethics Committee of the
Fourth People’s Hospital of Wuxi.
Strain identification
The morphology of strain B7 was examined by light
microscopy after Gram-staining and spore staining. The
physiological and biochemical characteristics of the isolate
was assessed according to previously described methods
[15]. Motility was determined using sulfide-indole-motility
medium. Fatty acid methyl esters were extracted and ana-
lyzed by the Sherlock Microbial Identification system
(MIDI, Newark, DE) according to the manufacturer’s in-
structions. All assays were performed in triplicate. The 16S
rRNA gene of strain B7 was amplified by PCR with
the universal primers 27F and 1541R and sequenced
[16]. Phylogenetic trees were constructed using the
neighbor-joining and maximum-parsimony algorithm
within MEGA4 [17]. The DNA-DNA hybridization
between B7 and Paenibacillus ehimensis IFO 15659T was
performed using the thermal denaturation method [14].Production and purification of active compounds
Strain B7 maintained on nutrient agar slants was inoculated
into 50 mL of nutrient broth and cultivated at 30°C for
24 h. The seed culture of strain B7 was transferred to a 2L
Erlenmeyer flask that contained 500 mL of the KL medium.
The culture was incubated on a rotary shaker (200 rpm) at
30°C for 3 d. After centrifugation at 4500 g for 30 min at
4°C, the cell-free supernatant was loaded onto a column
packed with Amberlite XAD-16 resin (Sigma, St. Louis,
MO). The column was washed with distilled water prior to
elution with stepwise gradients of aqueous methanol (30,
60, and 100%, v/v). Each fraction was concentrated and
assessed for activity using the paper disc method. The
active fraction was evaporated and dried before being
redissolved in acetonitrile. The concentrated solution was
then applied to a C18 SPE column (Hardwee, Germany).
The column was washed with five bed volumes of distilled
water, followed by five bed volumes of an acetonitrile/water
mixture (20:80, v/v). The fraction that contained the
active compounds was eluted from the column by
washing with three bed volumes of an acetonitrile/water
mixture (68:32, v/v). Further purification was performed
using a preparative HPLC system (Dalian Elite, Dalian,
China) that was equipped with an YMC-pack DOS-A C18
(5 μm, 250 × 20 mm) column. The mobile phase consisted
of Milli-Q water that contained 0.02% trifluoroacetic acid
and acetonitrile. A linear gradient of 15% to 55% aceto-
nitrile (40 min) was used for elution at a flow rate of
10 mL/min. UV detection was performed at a wavelength
of 210 nm. Fractions from multiple runs were collected
and combined for the subsequent antimicrobial activity
assays. The active fractions were passed through the
HPLC column two consecutive times.
Amino acid analysis
Approximately 300 μg of the purified compound in
0.4 ml of 6 M HCl with 0.1% phenol was hydrolyzed
at 110°C for 16 h. Amino acid analyses was performed
using ion-exchange chromatography with a Hitachi L-8900
amino acid analyzer (Tokyo, Japan) according to the
method described by Qian et al. [18]. The absolute
configuration of amino acids was determined using
1-fluoro-2,4-dinitrophenyl-5-D-leucinamide (D-FDLA)
and 1-fluoro-2,4-1-fluoro-2,4-dinitrophenyl-5-L-leuci-
namide (L-FDLA) as derivatizing agents. FDLA derivative
analysis was performed as previously described [19].
Mass spectrometry analysis
Electrospray ionization (ESI) mass spectra were acquired
in positive ion mode on a Thermo Finnigan LCQ mass
spectrometer (Thermo Electron Corporation, San Jose,
CA, USA). The ESI-mass spectrometry (MS) conditions
included a capillary voltage of 40 V, a source voltage of
4.5 kV, and a capillary temperature of 300°C. To obtain
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(CID) was applied to the purified lipopeptide antibiotics.
Antibacterial activity assay
During fermentation and purification, antimicrobial
activity was determined using the paper disc method [14].
The minimum inhibitory concentrations (MICs) of the
purified antibiotics were determined using a microbroth
dilution method according to the National Committee for
Clinical Laboratory Standards (2009). The final concentra-
tions of the antibiotics in the medium ranged from 1 to
64 μg/mL. MICs were measured after incubation at 37°C
for 20 h. To determine the effect of divalent cations on the
mode action of purified compounds, 10 mM CaCl2 or
MgCl2 was added to the test medium.
Time-kill assays
To further evaluate the antimicrobial characteristics of
the purified compounds, time-kill experiments were
performed as previously described [18]. The active com-
pound was added to a logarithmic-phase broth culture
of approximately 106 cfu/mL to yield concentrations of 0
and 4× MIC. The cultures were incubated with shaking
(120 rpm) at 37°C for 24 h. Surviving bacteria were
determined after 0, 1, 3, 6, and 24 h of incubation by
subculturing 100 μL serial dilutions of samples in 0.9%
sodium chloride on MH agar plates. A bactericidal effect
was defined as a ≥ 3 log10 cfu/mL decrease compared
with the initial inoculum.
Cytotoxicity assay
Cytotoxicity analysis was performed on the HEK293
human embryonic kidney cell line using the Cell Counting
Kit-8 (CCK-8; Dojindo, Tokyo, Japan). The HEK293T cells
were seeded into 96-well plates at 1 × 104 cells/well. After
incubation for 24 h at 37°C in a humidified atmosphere,
the medium was replaced with fresh medium that
contained active compound (1 μg/mL to 128 μg/mL,
in 2-fold increments). Three replicate wells were set
for each treatment. After incubation for another 48 h, cell
growth was assayed with CCK-8. The relative absorbance
was recorded at 450 nm.
Nucleotide accession number
The nucleotide sequence of 16S rRNA gene of strain B7
has been deposited in GenBank under the accession
number JX282195.
Results
Identification of strain B7
The bacteria strain B7 that is active against MRSA
ATCC 43300 and P. aeruginosa ATCC 27853 was
selected for further investigation. Morphologically, strain
B7 was characterized to be a rod-shaped, spore-forming,motile, Gram-positive bacterium. Aerobic growth of B7
occurred at a temperature between 20 and 50°C and a
pH between 6 and 8. Optimal conditions included a
temperature of 30°C and a pH of 7. The bacteria strain B7
was negative for urease and positive for catalase, oxidase,
methyl red test, and nitrate reduction. Starch, chitin, and
gelatin were hydrolyzed by strain B7. Acid was produced
from D-mannitol, D-gentiobiose, D-xylose, D-Mannose,
L-arabinose, mannitol, and glucose. The G +C content of
the strain DNA was 54.2%. The major fatty acid of strain
B7 was anteiso-C15:0, making up to 50.12% of the total
fatty acids, a characteristic of the genus Paenibacillus. The
B7 isolate and P. ehimensis IFO 15659T showed identical
16S rRNA gene sequences [20], which suggests that they
are members of the same species. This inference was
further confirmed by the DNA-DNA hybridization
results. The DNA-DNA re-association between strain
B7 and P. ehimensis IFO 15659T was 96.3%. All of these
characteristics supported the identification of the isolate
as a member of P. ehimensis. Thus, strain B7 was named
P. ehimensis B7.
Purification of antibiotics produced by P. ehimensis B7
P. ehimensis B7 grew well and produced active compounds
in the KL medium. Bioactivity was detectable approxi-
mately 20 h after inoculation and reached a maximum level
at 96 h. The cultures were separated into supernatant and
cell pellets by centrifugation. Before purification, the stabil-
ity of the antibiotics that were present in the culture super-
natant was investigated according to a previously described
method [15]. The active compounds were stable at a pH of
2.0 to 8.0, and their antimicrobial activities were also not
affected by heat treatment at 40 or 80°C for 1 h.
The antibiotics were easily absorbed from the culture
supernatant by Amberlite XAD-16 resin. The resin was
washed with distilled water and then eluted with stepwise
gradients of aqueous methanol. One fraction that was
eluted with 100% methanol exhibited the most significant
antimicrobial activity. This fraction was extracted with a
SPE cartridge and further separated by HPLC. Two active
compounds that were eluted at retention times of 28.2 and
26.4 min were obtained and named PE1 and PE2, respect-
ively. The final yield was approximately 17.6 mg/L for PE1
and 12.3 mg/L for PE2.
Structure analysis
ESI-MS analysis indicated that PE1 had a molecular mass
of 1114 Da, and PE2 had a molecular weight of 1,100 Da.
The two molecular masses differed from each other by
14 Da, suggesting that they were homologues. Amino
acid analysis demonstrated that these two compounds
had the same amino acid composition, and both of
them contained L- 2,4-diaminobutyric acid (L-Dab),
L-leucine (L-Leu), L-isoleucine (L-Ile), L-threonine
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with molar ratios of 3:2:1:1:1:1, which further confirmed
that they were structural close-related peptide antibiotics.
After alkaline hydrolysis (1 M KOH, 8 h, room
temperature), the purified compounds with protonated
molecular masses of 1,115 and 1,101 Da, yielded two
new products, with [M +H]+ ions of 1,133 and 1,119 Da,
respectively. The 18 Da increase in mass was attributed
to the hydrolysis of a lactone. This result indicated that
the two compounds were cyclic lipopeptide antibiotics.
The MS/MS spectrum of the doubly charged precursor
ion of the hydrolyzed compound at m/z 567.4 with a
mass of 1133 Da was shown in Figure 1. Successive frag-
mentations from the two termini of the ring-opened
lipopeptide resulted in b-type ions at m/z 1014.3, 901.2,
802.1, 702.1, 589.1, 441.9, 341.9, and 228.8, along with
corresponding y-type ions detected at m/z 905.2, 792.1,
692.0, 544.9, 431.9, 331.6, and 232.7. These fragment
ions allowed for the assignment of the following
sequence: Ile/Leu-Dab-Phe- Leu/Ile-Dab-Val-Leu/Ile-
Thr-OH. The b-type ions at m/z 228.8 corresponded to
fatty acid (FA)-Dab, which indicated that the fatty acyl
moiety has the elemental composition of C7H12O2.
The ring-opened PE2 with a mass [M +H]+ of
1,119 Da was also analyzed by CID. The tandem mass
spectrum of this derivative was shown in Figure 2. All of
the b-type ions that were generated from this doubly
charged precursor ion [M + 2H]2+ at m/z 560.3 were
14 Da less than those generated from the precursor ion
[M + 2H]2+ at m/z 567.4. However, the two y-type ion
series for the two compounds were almost the same inFigure 1 MS/MS spectrum of PE1 and its proposed amino acid seque
567.4 of the hydrolyzed PE1 of 1,133 Da. (B) Proposed amino acid sequencmass, which indicated that the two compounds had identi-
cal amino acid sequences but different fatty acid chains.
Similar to PE1, PE2 also produced a fragment ion at m/z
905.1, which corresponded to the loss of 214 Da from the
[M+H]+ ion. Examination of the neutral fragment that was
lost suggested that it contains a Dab residue and a fatty acyl
moiety (C6H10O2). These results further confirmed that the
two compounds were different in their fatty acyl moieties.
Apart from in the C-terminal amino acid (Thr), no
hydroxyl group was found in the peptide moieties of P.
ehimensis lipopeptides studied here. Thus, a lactone
linkage was only formed between the carboxyl group of
the C-terminal and the hydroxyl group of fatty acid
moieties. The proposed structures for PE1 and PE2
are showed in Figure 3.
Antimicrobial activities of the purified compounds
The antimicrobial activities of the purified compounds
PE1 and PE2 were measured using micro dilution
methods. Table 1 showed that PE1 and PE2 both had a
similar level of strong activity against all of the tested
Gram-positive and Gram-negative pathogens as well as
Candida albicans. The MICs of the compounds were
lower than those of commercial polymyxin B in the
cases of Gram-positive bacteria. In the case of E. coli
ATCC 35318, E. coli 5539, and P. aeruginosa ATCC
27853, the MICs of PE1 and PE2 were higher than that
of polymyxin B. Interestingly, P. aeruginosa 5215, a pan-
drug resistant clinical isolate, was highly sensitive to PE1
and PE2, with MICs of 2 μg/mL that was slightly lower
than that of polymyxin B.nce. (A) MS/MS spectrum of the doubly charged precursor ion at m/z
e of PE1.
Figure 2 MS/MS spectrum of PE2 and its proposed amino acid sequence. (A) MS/MS spectrum of the doubly charged precursor ion at m/z
560.3 of the hydrolyzed PE2 of 1,119 Da. (B) Proposed amino acid sequence of PE2.
Table 1 The minimum inhibitory concentrations (MICs) of
lipopeptide antibiotics (PE1 and PE2) produced by
Paenibacillus ehimensis B7
Indicator strain MIC (μg/mL)
PE1 PE2 polymyxin B
Staphylococcus epidermidis CMCC 26069 1 1 4
Staphylococcus aureus ATCC 25923 8 8 64
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To further evaluate the growth inhibition effect of newly
isolated antibiotics, killing experiments of PE1 and PE2
against S. aureus ATCC 43300 and P. aeruginosa ATCC
27853 were performed. The time-kill curves of PE1
against both strains were similar to PE2 (Figure 4). In
the case of P. aeruginosa ATCC 27853, all of the tested
antibiotics at 4 ×MIC rapidly reduced the number of
viable cells of this strain by at least 3 orders of magnitude
over the first 3 h of exposure, and no bacteria could be
detected after a 24 h incubation. In the case of S. aureus
ATCC 43300, the number of viable cells counted also
dramatically decreased within a period of 3 h following
the addition of these two compounds, although substantial
re-growth occurred after 24 h. Thus, PE1 and PE2 were
determined to be bactericidal at high concentrations,
which is consistent with the characteristics of other
cationic cyclic lipopeptides [21,22].
Effect of divalent cations on antibacterial activity
To determine the effect of divalent cations on the antibac-
terial activity of the lipopeptides that are produced by P.
ehimensis B7, the MICs of PE1 against S. aureus ATCC
43300 and P. aeruginosa ATCC 27853 were determined inFigure 3 Proposed structures of PE1 and PE2 produced by
Paenibacillus ehimensis B7.MH medium with 10 mM Ca2+ or Mg2+. In normal
medium, the MICs of PE1 for S. aureus ATCC 43300 and
P. aeruginosa ATCC 27853 were 4 and 8 μg/mL, respect-
ively. However, the MICs of PE1 for S. aureus ATCC
43300 and P. aeruginosa ATCC 27853 increased to 8
and >64 μg/mL, respectively, when 10 mM CaCl2 was
added to the test medium. Similar results were obtained
when Mg2+ was added instead of Ca2+ (Table 2).
Cytotoxicity
The cytotoxicity of the purified compounds (PE1 and PE2)
against mammalian cells was tested by the CCK-8 assay.
PE1 and PE2 showed little cytotoxicity against HEK293T
cells (treatment time, 24 h) at all of concentrations that
were tested (1 μg/mL to 128 μg/mL) (Figure 5).Staphylococcus aureus ATCC 43300 4 4 32
Escherichia coli ATCC 35318 8 8 2
Escherichia coli 5539 4 4 1
Pseudomonas aeruginosa ATCC 27853 8 4 2
Pseudomonas aeruginosa 5215 2 2 4
Candida albicans ATCC 10231 8 8 64
Figure 4 Growth curves of Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 43300 treated with 4 ×MIC peptide
antibiotics. The curves are viable cell concentrations plotted against time. In two panels, non-antibiotic control, open diamond; 4 ×MIC PE1, filled
circle; 4 ×MIC PE2, filled triangle; 4 ×MIC polymyxin B, filled diamond. For the two strains in the present study, time-kill assays were independently
performed 3 times and similar results were obtained. Mean values of the triplicate cfu/mL measurements from a single experiment are plotted.
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In the present study, B7, a new bacterial strain with potent
antimicrobial activity was isolated from a dairy waste
sample, and identified as P. ehimensis. Phylogenetic analysis
based on 16S rRNA gene indicated that the isolate was
closely related to P. elgii, P. koreensis, and P. tianmuensis
(data not shown). This group of bacteria produces diverse
antimicrobial agents, including lipopeptides [15,22,23],
lantibiotics [24] and macrolide [14]. Interestingly, most
extensively described lipopeptide antibiotics from this
group of bacteria contain a high percentage of both Dab
and a C6-C7 N-terminal fatty acyl chain [15,22].
The active compounds (PE1 and PE2) that are pro-
duced by P. ehimensis B7 were structurally similar to the
lipopeptide polypeptins (A and B) that were previously
isolated from Bacillus circulum [25]. Polypeptin is a
group of polypeptide antibiotics composed of a cyclic
nonapeptide moiety and a fatty acid side chain. To date,
five polypeptin-type antibiotics, including polypeptin A,
polypeptin B, permetin A, BMY-28160, and pelgipeptin
D, have been extensively described [25-28]. Polypeptins
A and B, which have the same molecular formula, have
identical amino acid moieties but vary in the structure of
fatty acids. BMY-28160 and permetin A only differ from
each other at position 2 in peptide moieties (i.e., L-Val isTable 2 Effect of divalent cations on antibacterial activity








PE1 + 10 mM CaCl2 >64 8
PE1 + 10 mM MgCl2 >64 8in BMY-28160, and L-Ile in permetin A). Pelgipeptin D
and permetin A only differ from each other in the fatty
acid moiety, while permetin A differs from polypeptin A
only in the amino acid at position 9 (i.e., L-Ser is present
in permetin A, and L-Thr in polypeptin A). Polypeptin-
type antibiotics were known to have a broad spectrum of
antimicrobial activity against many Gram-positive and
Gram-negative bacteria [25]. The molecular mass of PE1
was identical to that of polypeptin A and B, and the
amino acid sequences and antimicrobial spectra were
extremely similar, suggesting PE1 and polypeptin (A or B)
are most likely the same compound. However, PE2 was
characterized as a new analog of polypeptin because PE2
and polypeptin contained identical peptide moieties, but
differed from each other by a molecular mass of 14 DaFigure 5 Cytotoxicity of PE1 and PE2 to mammalian cells.
Cytotoxicity of PE1 and PE2 to HEK293T was measured with the
CCK-8 assay. The concentrations of PE1 and PE2 ranged from 0 to
128 μg/mL. The positive control was 0.1% Triton X-100.
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guished by tandem mass spectrometry, there are two
reasons for us to assign Ile at position 2, and Leu at posi-
tions 5 and 8 in the PE peptide antibiotics (Figure 4). Firstly,
the amino acid compositions of PE and polypeptin are
identical, including the molar ratios of amino acids and
their absolute configurations. Secondly, positions 5 and 8 of
the peptide moieties in all of the extensively described
members of polypeptin are Leu, whereas Ile or Val is
present in their peptide moieties at position 2 [15,25].
The active modes of cationic lipopeptides generally
involve the interaction of positive charged residues with
bacterial cell wall, which is normally stabilized by divalent
cations (Ca2+ and Mg2+) [8,29,30]. This is consistent with
our results that the addition of 10 mM Ca2+ or Mg2+ sig-
nificantly reduced the susceptibility of Gram-negative and
Gram-positive bacteria to lipopeptides from P. ehimensis.
In addition to positive residues, the fatty acyl chain and
amphipathic structure also contribute to the antimicrobial
activity of cationic peptides [12,31]. Although polypeptin
and polymyxin are structurally related cyclic lipopeptides
with several basic amino acids, their antimicrobial potencies
and spectra are significantly different. Polypeptin has a
broad-spectrum activity against Gram-positive and Gram-
negative bacteria, whereas polymyxin is potently active
mainly against Gram-negative bacteria. The selectivity of
lipopeptide antibiotics may be attributable to their differen-
tial binding affinities to the external and/or cytoplasmic
membrane of Gram-negative and Gram-positive bac-
teria. Understanding the action mode of polypeptin
may provide some useful clues toward developing
novel lipopeptide antibiotics.Conclusion
In conclusion, two active compounds (PE1 and PE2) were
obtained from the newly isolated strain P. ehimensis.
Structural analysis indicated that they were analogs of
polypeptin, and PE2 was characterized as a novel analog
of polypeptin. These two compounds showed potent
activity against Gram-positive and Gram-negative bacter-
ial pathogens, including MRSA and pan-drug resistant
P. aeruginosa. Although the present results provide
some valuable information about the cyclic lipopeptide
antibiotics that are produced by Paenibacillus ehimensis,
further studies are needed to determine their potential
clinical utility.
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